Soleno's First Earnings as a Fifty-Three Dollar Certainty

Soleno Therapeutics (SLNO) reports Q1 2026 earnings on May 13, 2026, with analysts expecting $0.91 per share—a dramatic turnaround from the $0.09 loss in the same quarter last year. The central question is whether the company can sustain the profitability momentum that emerged in late 2025, or if the recent miss in Q4 2025 signals execution challenges ahead. With analyst sentiment deteriorating sharply and the stock trading near its 200-day moving average, this report will test investor confidence in SLNO's commercial trajectory.

Part 1: Earnings Preview

Soleno Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for rare diseases, with its lead commercial product VYKAT XR (diazoxide choline) targeting hyperphagia in Prader-Willi syndrome patients. The company leverages precision medicine to address genetic and metabolic dysfunctions in underserved patient populations.

Soleno reports Q1 2026 earnings on May 13, 2026, with the consensus estimate calling for $0.91 per share. The company most recently reported Q4 2025 earnings of $0.59 per share, which missed the $0.73 estimate by 19.18%. Year-over-year, the Q1 2026 estimate represents a remarkable +1,111.11% growth from the $0.09 loss reported in Q1 2025, reflecting the company's transition from clinical-stage losses to commercial profitability.

Three key themes define this earnings story:

Commercial Execution and VYKAT XR Uptake: Following FDA approval and launch, investors are focused on prescription trends, patient enrollment, and revenue ramp for VYKAT XR. The company's ability to demonstrate sustained commercial traction will be critical, especially after the Q4 miss raised questions about execution consistency.

Neurocrine Acquisition Integration: In early April 2026, Neurocrine announced plans to acquire Soleno in a multi-billion dollar deal. Investors will scrutinize management commentary on integration timelines, regulatory approvals, and how the pending transaction affects near-term operations and strategic priorities.

Pipeline Development and PMM2-CDG Progress: Beyond VYKAT XR, Soleno's SEZ982 candidate for PMM2-CDG represents a significant pipeline opportunity. Any updates on clinical trial progress, regulatory interactions, or development timelines could influence the long-term investment thesis, particularly as the company transitions under Neurocrine's ownership.

Analyst commentary ahead of the release reflects caution. Multiple firms downgraded SLNO in April 2026 following the acquisition announcement, with Wells Fargo, HC Wainwright, TD Cowen, Baird, Oppenheimer, and Stifel all moving to Hold or Neutral ratings. The consensus shifted from optimistic growth projections to a more conservative stance focused on deal completion rather than standalone fundamentals. Wells Fargo cut its price target from $110 to $53, while TD Cowen reduced its target from $85 to $53, reflecting the acquisition price as the new ceiling for near-term upside.

Part 2: Historical Earnings Performance

Soleno's earnings track record shows a company in transition from consistent losses to emerging profitability. In Q1 2025, the company posted a $0.95 loss against a $0.93 loss estimate, a modest 2.15% miss. The turning point came in Q2 2025, when SLNO delivered a $0.09 loss versus the $0.53 loss estimate—an 83.02% beat that marked the beginning of better-than-expected performance.

The momentum accelerated dramatically in Q3 2025, when the company reported $0.47 in earnings with no analyst estimate available for comparison. Q4 2025 continued the positive trend with $0.80 per share beating the $0.64 estimate by 25.00%. However, the most recent quarter (Q4 2025, reported in March 2026) showed a stumble: $0.59 per share missed the $0.73 estimate by 19.18%, breaking a three-quarter streak of beats.

The pattern reveals a company that transitioned to profitability in mid-2025 and generally exceeded expectations through year-end, but the recent miss raises questions about consistency. The magnitude of beats in Q2 and Q4 2025 (83.02% and 25.00%) suggests analysts were initially conservative in modeling the commercial ramp, but the Q4 2025 miss indicates either execution challenges or overly optimistic revised estimates.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Soleno typically reports earnings before market open, meaning Day 0 captures the first full trading session reaction while Day +1 reflects follow-through momentum.

Historical price behavior around earnings shows significant volatility, with the average absolute Day 0 move of 2.41% expanding to 7.00% by Day +1. The Day +1 range averages 9.77%, indicating substantial intraday swings as investors digest results and guidance.

The most dramatic reaction came after the November 2025 report, when the stock fell 2.74% on Day 0 but then plunged 26.59% on Day +1—the largest single-day move in the dataset. This outsized reaction likely reflected concerns about the sustainability of the profitability inflection. In contrast, the February 2025 report saw a modest 0.24% decline on Day 0 followed by an 8.51% rally on Day +1, demonstrating how initial reactions can reverse.

More recent reports show mixed patterns: the February 2026 report (Q4 2025 results) saw a 4.72% Day 0 gain that reversed to a 7.12% Day +1 decline, consistent with the earnings miss. The August 2025 report showed minimal Day 0 movement (0.54% decline) but a 3.05% Day +1 drop. Investors should expect meaningful volatility in both directions, with Day +1 moves frequently exceeding Day 0 reactions as the market fully processes results and management commentary.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of just 0.05% through the May 15 expiration, dramatically lower than the historical average Day 0 move of 2.41% and Day +1 move of 7.00%. This unusually subdued implied volatility likely reflects the pending Neurocrine acquisition, which has effectively capped upside near the $53 deal price and reduced uncertainty about the stock's near-term trajectory regardless of earnings results.

Part 3: What Analysts Are Saying

Analyst sentiment on Soleno has deteriorated sharply following the April 2026 acquisition announcement. The current consensus stands at 3.00 (Hold), with all 11 analysts now rating the stock a Hold. This represents a significant shift from one month ago, when the average recommendation was 3.18 and the firm still had 1 Strong Buy rating alongside 10 Holds.

The rating distribution tells the story: 0 Strong Buys, 0 Moderate Buys, 11 Holds, 0 Moderate Sells, and 0 Strong Sells. One month ago, the breakdown was 1 Strong Buy, 0 Moderate Buys, 10 Holds, 0 Moderate Sells, and 0 Strong Sells. The complete absence of buy ratings reflects the market's view that upside is now limited by the acquisition price.

The average price target of $53.00 (with high and low estimates both at $53.00) sits just 0.13% above the current price of $52.93, indicating analysts see minimal upside potential. This tight clustering around $53 reflects the Neurocrine deal price, which has become the effective ceiling for the stock. The uniformity of targets suggests the investment case has shifted from fundamental analysis to deal arbitrage, with the primary risk now being deal completion rather than operational performance.

Part 4: Technical Picture

The Barchart Technical Opinion shows a Buy signal at 24%, representing a significant improvement from last week's Buy at 8% but still weaker than last month's Sell at 24%. This recent strengthening suggests short-term momentum has turned positive heading into earnings.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal indicates near-term momentum is positive but not overwhelming, consistent with the stock's recent consolidation near the acquisition price
• Medium-term (Hold): Neutral reading suggests the intermediate timeframe lacks directional conviction, likely reflecting uncertainty around deal timing and earnings impact
• Long-term (Hold): Neutral long-term signal indicates the broader trend has stabilized after the acquisition announcement volatility

Trend Characteristics: The Minimum strength and Weakest direction readings indicate the current trend environment is fragile and lacks conviction, suggesting the stock is vulnerable to sharp moves on any earnings surprise or deal-related news.

From a moving average perspective, SLNO trades above its 10-day ($52.90), 20-day ($52.80), 50-day ($44.63), and 100-day ($43.72) moving averages, but below its 5-day ($52.94) and 200-day ($53.04) moving averages. The stock is essentially pinned between its 5-day and 200-day averages, with the 200-day at $53.04 serving as resistance that aligns closely with the acquisition price.

The technical setup heading into earnings is neutral to cautious. While the stock holds above most key moving averages, the proximity to the $53 acquisition price creates a natural ceiling that limits upside potential regardless of earnings quality. The 200-day moving average at $53.04 reinforces this resistance level. The weak trend characteristics (Minimum strength, Weakest direction) suggest the stock lacks the momentum to break meaningfully higher, while the extremely low options-implied move (0.05%) indicates the market expects muted volatility. Investors should view the technical picture as range-bound, with the $52.70-$53.00 zone likely containing most post-earnings price action unless deal-related news emerges.